Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice

Clinical and Experimental Rheumatology

Volumn 34, Issue 1, 2016, Pages 111-118

  Zhang, Yongfeng ^a   Zheng, Yi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Caspase 1 inhibitor; Pro inflammatory cytokines; Rheumatoid arthritis; VX765

Indexed keywords

BELNACASAN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; 1-(2-((1-(4-AMINO-3-CHLOROPHENYL)METHANOYL)AMINO)-3,3-DIMETHYLBUTANOYL)PYRROLIDINE-2-CARBOXYLIC ACID; 4 AMINOBENZOIC ACID DERIVATIVE; AUTACOID; BIOLOGICAL MARKER; CASPASE INHIBITOR; COLLAGEN; DIPEPTIDE; IL1B PROTEIN, MOUSE; IL33 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; BONE MARROW EDEMA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNIZATION; JOINT RADIOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SYNOVITIS; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHROGRAPHY; BLOOD; CHEMICALLY INDUCED; DBA MOUSE; DRUG EFFECTS; ENZYMOLOGY; JOINT; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHROGRAPHY; BIOMARKERS; CASPASE 1; CASPASE INHIBITORS; COLLAGEN; DIPEPTIDES; DISEASE PROGRESSION; INFLAMMATION MEDIATORS; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTERLEUKIN-33; JOINTS; MALE; MICE, INBRED DBA; PARA-AMINOBENZOATES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 84958748212     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. + cells from patients with rheumatoid arthritis: association with inflammation and vascular involvement. Clin Exp Rheumatol 2014; 32: 922-9.
2. McINNES IB, CRUWYS S, BOWERS K, BRADDOCK M: Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism. Clin Exp Rheumatol 2014; 32: 878-82.
3. PASTORE S, PALONI G, CAORSI R et al.: Serum amyloid protein A concentration in cryopyrin-associated periodic syndromes patients treated with interleukin-1 beta antagonist. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S63-6.
4. CHO ML, JUNG YO, MOON YM et al.: Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 2006; 103: 159-66.
5. FLEISCHMANN RM, TESSER J, SCHIFF MH et al.: Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-12.
6. KAMRADT T, DRUBE S: A complicated liaison:IL-33 and IL-33R in arthritis pathogenesis. Arthritis Res Ther 2013; 15: 115.
7. VOLIN MV, KOCH AE: Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res 2011; 31: 745-51.
8. GRACIE JA: Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 2004; 136: 402-4.
9. HASHIZUME M, TAN SL, TAKANO J et al.:Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights. Int Rev Immunol 2014.
10. WANG D, LI Y, LIU Y, SHI G: The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol 2014; 15:542-8.
11. MIGITA K, KOMORI A, TORIGOSHI T et al.: :CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther 2011; 13:R72.
12. VYAS D, O'DELL KM, BANDY JL, BOYCE EG:Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013; 47: 1524-31.
13. WANNAMAKER W, DAVIES R, NAMCHUK M et al.: (S)-1-((S)-2-([1-(4-amino-3-chlorophenyl)-- methanoyl]-amino)-3,3-dimethylbutanoyl)- pyrrolidine-2-carboxylicacid- ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 2007; 321: 509-16.
14. BOXER MB, QUINN AM, SHEN M et al.: A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. Chem Med Chem 2010; 5: 730-8.
15. LE GT, ABBENANTE G: Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. Curr Med Chem 2005; 12: 2963-77.
16. JOOSTEN LA, HELSEN MM, VAN DE LOO FA, van den BERG WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 2008; 58 (2 Suppl.): S110-22.
17. SASAI M, SAEKI Y, OHSHIMA S et al.: Delayed onset and reduced severity of collageninduced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42: 1635-43.
18. BRAND DD, LATHAM KA, ROSLONIEC EF: Collagen-induced arthritis. Nat Protoc 2007; 2: 1269-75.
19. DU F, LU LJ, FU Q et al.: T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther 2008; 10: R136.
20. Le GOFF B, SOLTNER E, CHARRIER C et al.: A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009; 11: R185.
21. KOIZUMI F, MATSUNO H, WAKAKI K, ISHII Y, KURASHIGE Y, NAKAMURA H: Synovitis in rheumatoid arthritis: scoring of characteristic histopathological features. Pathol Int 1999; 49: 298-304.
22. RATKAY LG, CHOWDHARY RK, IAMAROON A et al.: Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 1998; 41: 525-34.
23. BERGSBAKEN T, FINK SL, COOKSON BT:Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109.
24. MAROSO M, BALOSSO S, RAVIZZA T et al.: Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 2011; 8: 304-15.
25. STACK JH, BEAUMONT K, LARSEN PD et al.: IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 2005; 175: 2630-4.
26. BAILLET A, GOSSEC L, PATERNOTTE S et al.:Evaluation of serum IL-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: Results from the ESPOIR cohort. Arthritis Care Res (Hoboken) 2014.
27. CHANG SH, CHOI BY, CHOI J et al.: Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. Rheumatol Int 2015; 35: 71-9.
28. CHEN YT, HOU CH, HOU SM, LIU JF: The effects of amphiregulin induced MMP-13 production in human osteoarthritis synovial fibroblast. Mediators Inflamm 2014; 2014:759028.
29. MA JD, ZHOU JJ, ZHENG DH et al.: Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm 2014; 2014: 179284.
30. MALEMUD CJ: Intracellular Signaling Pathways in Rheumatoid Arthritis. J Clin Cell Immunol 2013; 4: 160.
31. NISHIKAWA M, MYOUI A, TOMITA T, TAKAHI K, NAMPEI A, YOSHIKAWA H: Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogenactivated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670-81.
32. SHINOZAKI T, TAKAGISHI K, TSUTSUMI S et al.: Effects of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. Mod Rheumatol 2001; 11: 300-3.
33. SONG GG, BAE SC, LEE YH: Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med 2014; 29:656-63.